venetoclax,obinutuzumab
abbvie,roche
['lymsm', 'venetoclax', 'cll']
treatment sequencing: cumulative costs are lower when starting with time-limited venetoclax + obintuzumab in first-line cll (compared to starting with oral continuous therapy), in both tp53 wt &amp; mut disease. important implications for health systems. #ash22 #lymsm #costsofcare 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????